Clik here to view.
First definitive classification system for Oligometastatic Disease
Researchers develop the first definitive classification system for Oligometastatic DiseaseOligometastatic disease (OMD) is an intermediate state where a primary cancer has spread (metastasised) to a...
View ArticleClik here to view.
ESTRO EORTC OligoCare Workshop
ESTRO EORTC OligoCare Workshop30 June (16:00-19:00 CET) and 1 July (16:00-17:30 CET) Workshop aim Participants will learn about the current clinical status and recent scientific developments in the...
View ArticleClik here to view.
A 1000 patients enrolled in the OligoCare cohort!
A 1000 patients enrolled in the OligoCare cohort!This week, the 1000th patient has been enrolled in the OligoCare cohort. A HUGE thank you to all the sites that have contributed to reaching this...
View ArticleClik here to view.
The 1500th patient has been enrolled in the E²-RADIatE cohort OLIGOCARE...
The 1500th patient has been enrolled in the E2‑RADIatE cohort OLIGOCARE (RP-1822)It is a great pleasure to announce that the 1500th patient has been enrolled in the OligoCare cohort of the...
View ArticleClik here to view.
ESTRO and EORTC consensus on re-irradiation
ESTRO and EORTC consensus on re-irradiationRe-irradiation can be considered for local recurrence or new tumours adjacent to a previously irradiated site to achieve durable local control for patients...
View ArticleClik here to view.
OligoCare recruitment update
OligoCare recruitment updateThe OligoCare cohort of E²-RADIatE continues to recruit very well with a total of 1747 patients enrolled (cut-off 01st December 2022) at 45 institutions across Austria,...
View ArticleClik here to view.
Metastases-directed stereotactic body radiotherapy in combination with...
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapyStereotactic body radiotherapy (SBRT) for patients with metastatic cancer, especially when...
View ArticleClik here to view.
OligoCare: 2000 patients enrolled
OligoCare: 2000 patients enrolledWe are delighted to announce that on the 11th of April 2023, the RP-1822 OligoCare cohort of the 1811-E²-RADIatE platform successfully enrolled its 2000th patient,...
View ArticleClik here to view.
ReCare: first site active
ReCare: first site activeWe are very happy to announce that the first site for ReCare has been activated. ReCare (EORTC 2011-RP) is a cohort of the E2-RADIatE platform that focuses on cancer patients...
View ArticleVirtual symposium on “Hot topics and challenges in SBRT for oligometastatic...
Virtual symposium on “Hot topics and challenges in SBRT for oligometastatic disease”On 30 January 2024, EORTC and the European Society for Radiotherapy and Oncology (ESTRO) collaboratively organised a...
View ArticleClik here to view.
Health-related quality of life in men with oligometastatic prostate cancer...
Health-related quality of life in men with oligometastatic prostate cancer following metastases-directed stereotactic body radiotherapy: Real-world data from the E2-RADIatE OligoCare cohortObjective To...
View ArticleClik here to view.
Cancer-specific dose and fractionation schedules in stereotactic body...
Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare studyBackground and...
View ArticleClik here to view.
Acute toxicity in patients with oligometastatic cancer following...
Acute toxicity in patients with oligometastatic cancer following metastasis-directed stereotactic body radiotherapy: An interim analysis of the E2-RADIatE OligoCare cohortAim To evaluate acute toxicity...
View Article